{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:37:04Z","timestamp":1789994224591,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Candidaemia is the most common form of invasive candidiasis. Resistant\n                      <jats:italic>Candida<\/jats:italic>\n                      blood stream infection (BSI) is rising, with limitations on the development of broader-spectrum antifungal agents worldwide. Our study aimed to identify the occurrence of antifungal-resistant candidaemia and the distribution of these species, determine the risk factors associated with antifungal resistance and evaluate the association of antifungal-resistant candidaemia with the length of intensive care unit (ICU) and hospital stay and with 30-day mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted at King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia. Adult patients diagnosed with candidaemia from January 2006 to December 2017 were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 196 BSIs were identified in 94 males (49.74%) and 95 females (50.26%).\n                      <jats:italic>C. glabrata<\/jats:italic>\n                      was the most commonly isolated\n                      <jats:italic>Candida<\/jats:italic>\n                      species, with 59 (30%), followed by\n                      <jats:italic>C. albicans<\/jats:italic>\n                      with 46 (23%). Susceptibility data were available for 122\/189 patients, of whom 26\/122 (21%) were resistant to one or more antifungals.\n                      <jats:italic>C. parapsilosis<\/jats:italic>\n                      with available sensitivity data were found in 30\/122 isolates, of which 10\/30 (33%) were resistant to fluconazole. Risk factors significantly associated with antifungal-resistant candidaemia included previous echinocandin exposure (odds ratio (OR) =1.38; 95% confidence interval (CI) (1.02\u20131.85);\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.006) and invasive ventilation (OR\u2009=\u20091.3; 95% CI (1.08\u20131.57);\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.005). The median length of ICU stay was 29\u2009days [range 12\u201349\u2009days] in the antifungal-resistant group and 18\u2009days [range 6.7\u201337.5\u2009days] in the antifungal-sensitive group (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.28). The median length of hospital stay was 51\u2009days [range 21\u2013138\u2009days] in the antifungal-resistant group and 35\u2009days [range 17\u201377\u2009days] in the antifungal-sensitive group (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.09). Thirty-day mortality was 15 (57.7%) and 54 (56.25%) among the antifungal-resistant and antifungal-sensitive groups, respectively (OR\u2009=\u20091.01; 95% CI (0.84\u20131.21);\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.89).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our results indicate a high frequancy of non-\n                      <jats:italic>C. albicans candidaemia<\/jats:italic>\n                      . The rise in\n                      <jats:italic>C. parapsilosis<\/jats:italic>\n                      resistance to fluconazole is alarming. Further studies are required to confirm this finding.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-019-4710-z","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T08:02:23Z","timestamp":1579248143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Antifungal resistance in patients with Candidaemia: a retrospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-1606","authenticated-orcid":false,"given":"Namareq F.","family":"Aldardeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadiel","family":"Albar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majda","family":"Al-Attas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelmoneim","family":"Eldali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Qutub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Hassanien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem","family":"Alraddadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"issue":"1","key":"4710_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2012.02.001","volume":"73","author":"D Diekema","year":"2012","unstructured":"Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73(1):45\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"4710_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","volume":"39","author":"DH Kett","year":"2011","unstructured":"Kett DH, Azoulay E, Echeverria PM, Vincent JL. Extended prevalence of infection in ICUSGoI. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39(4):665\u201370.","journal-title":"Crit Care Med"},{"issue":"3","key":"4710_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective Nationwide surveillance study. Clin Infect Dis. 2004;39(3):309\u201317.","journal-title":"Clin Infect Dis"},{"issue":"13","key":"4710_CR4","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198\u2013208.","journal-title":"N Engl J Med"},{"issue":"4","key":"4710_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ1194","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1\u201350.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4710_CR6","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1128\/AAC.00479-10","volume":"54","author":"J Garnacho-Montero","year":"2010","unstructured":"Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E. Ruiz Perez de Pipaon M, Hernandez-Caballero C, Aznar-Martin J, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother. 2010;54(8):3149\u201354.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4710_CR7","doi-asserted-by":"publisher","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","volume":"2","author":"S Vallabhaneni","year":"2015","unstructured":"Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG, et al. Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008\u20132014. Open Forum Infect Dis. 2015;2(4):ofv163.","journal-title":"Open Forum Infect Dis."},{"issue":"3\u20134","key":"4710_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.5144\/0256-4947.2001.178","volume":"21","author":"DH Akbar","year":"2001","unstructured":"Akbar DH, Tahawi AT. Candidemia at a university hospital: epidemiology, risk factors and predictors of mortality. Ann Saudi Med. 2001;21(3\u20134):178\u201382.","journal-title":"Ann Saudi Med"},{"issue":"3","key":"4710_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ijid.2006.03.003","volume":"11","author":"JA Al-Tawfiq","year":"2007","unstructured":"Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004. Int J Infect Dis. 2007;11(3):239\u201344.","journal-title":"Int J Infect Dis"},{"key":"4710_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijid.2013.12.012","volume":"21","author":"AH Al Thaqafi","year":"2014","unstructured":"Al Thaqafi AH, Farahat FM, Al Harbi MI, Al Amri AF, Perfect JR. Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. Int J Infect Dis. 2014;21:5\u20139.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"4710_CR11","first-page":"566","volume":"25","author":"AM Aljasser","year":"2004","unstructured":"Aljasser AM, Elkhizzi NA. Distribution of Candida species among bloodstream isolates. Saudi Med J. 2004;25(5):566\u20139.","journal-title":"Saudi Med J"},{"issue":"4","key":"4710_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1128\/AAC.50.4.1287-1292.2006","volume":"50","author":"BJ Park","year":"2006","unstructured":"Park BJ, Arthington-Skaggs BA, Hajjeh RA, Iqbal N, Ciblak MA, Lee-Yang W, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother. 2006;50(4):1287\u201392.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4710_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","volume":"71","author":"SC Chen","year":"2011","unstructured":"Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11\u201341.","journal-title":"Drugs."},{"issue":"1","key":"4710_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ajic.2009.06.014","volume":"38","author":"C Moran","year":"2010","unstructured":"Moran C, Grussemeyer CA, Spalding JR, Benjamin DK Jr, Reed SD. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control. 2010;38(1):78\u201380.","journal-title":"Am J Infect Control"},{"issue":"10","key":"4710_CR15","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/cid\/cis697","volume":"55","author":"AA Cleveland","year":"2012","unstructured":"Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012;55(10):1352\u201361.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4710_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1128\/JCM.06112-11","volume":"50","author":"MA Pfaller","year":"2012","unstructured":"Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50(4):1199\u2013203.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"4710_CR17","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1016\/j.ijid.2010.04.006","volume":"14","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14(11):e954\u201366.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"4710_CR18","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1128\/AAC.05947-11","volume":"56","author":"R Ben-Ami","year":"2012","unstructured":"Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother. 2012;56(5):2518\u201323.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4710_CR19","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/AAC.01128-10","volume":"55","author":"O Lortholary","year":"2011","unstructured":"Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55(2):532\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4710_CR20","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1128\/AAC.00019-12","volume":"56","author":"DN Shah","year":"2012","unstructured":"Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012;56(6):3239\u201343.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"4710_CR21","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1128\/AAC.01177-15","volume":"59","author":"AC Souza","year":"2015","unstructured":"Souza AC, Fuchs BB, Pinhati HM, Siqueira RA, Hagen F, Meis JF, et al. Candida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected galleria mellonella larvae. Antimicrob Agents Chemother. 2015;59(10):6581\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4710_CR22","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3201\/eid2011.140685","volume":"20","author":"D Farmakiotis","year":"2014","unstructured":"Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis. 2014;20(11):1833\u201340.","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"4710_CR23","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1128\/AAC.00466-11","volume":"55","author":"E Canton","year":"2011","unstructured":"Canton E, Peman J, Quindos G, Eraso E, Miranda-Zapico I, Alvarez M, et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother. 2011;55(12):5590\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4710_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","volume":"20","author":"MA Pfaller","year":"2007","unstructured":"Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133\u201363.","journal-title":"Clin Microbiol Rev"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4710-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4710-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4710-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T19:06:07Z","timestamp":1610737567000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4710-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4710"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4710-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.9663\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9663\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9663\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9663\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"9 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia (IRB# 17_02).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AH works at Pfizer, anti infectives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}